Heart failure with reduced ejection fraction affects tens of millions globally, diagnosed via natriuretic peptides and cardiac imaging, with evolving treatment approaches.
70 million affected globallyHFrEF has 2% prevalence in Europe/North America, diagnosed via BNP and cardiac imaging
What the researchers found
HFrEF accounts for approximately half of all heart failure cases, with diagnosis relying on natriuretic peptide levels, cardiac imaging, and clinical signs/symptoms.
Why it matters
HFrEF affects 70 million people globally and is a leading cause of hospitalization, disability, and death. Evidence-based treatment can significantly improve outcomes.
How the study worked
Comprehensive clinical review of heart failure with reduced ejection fraction epidemiology, diagnosis, and management.
What this study cannot tell us
Review article — provides overview rather than new data. Treatment recommendations may evolve as new evidence emerges.
How to read the evidence
Authoritative clinical review — synthesizes established evidence and guidelines.
When this study was published
Published in 2026; reflects current diagnostic and treatment standards.
The bigger picture
Advances in HFrEF treatment — including neurohormonal blockers, devices, and now GLP-1 drugs — have transformed survival, but the condition remains a major global health burden.
Questions still open
- How will GLP-1 drugs and other new therapies change HFrEF management?
- Can early detection via natriuretic peptide screening reduce HFrEF burden?
Common questions
What is heart failure with reduced ejection fraction?
How is HFrEF diagnosed?
Read the original research
Heart failure with reduced ejection fraction.
Lancet (London, England), 407(10527), 529-542
Citation
Cannata, Antonio; Crespo-Leiro, Maria Generosa; Bromage, Daniel I; Ruschitzka, Frank; McDonagh, Theresa A. (2026). Heart failure with reduced ejection fraction.. Lancet (London, England), 407(10527), 529-542. https://doi.org/10.1016/S0140-6736(25)01851-3